KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Income from Continuing Operations (2016 - 2025)

NovoCure's Income from Continuing Operations history spans 12 years, with the latest figure at 24499000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 62.84% year-over-year to 24499000.0; the TTM value through Dec 2025 reached 136227000.0, up 19.21%, while the annual FY2025 figure was 136227000.0, 19.21% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 24499000.0 at NovoCure, up from 37270000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 4128000.0 in Q1 2021 and bottomed at 65922000.0 in Q4 2024.
  • The 5-year median for Income from Continuing Operations is 33847000.0 (2024), against an average of 33139100.0.
  • The largest annual shift saw Income from Continuing Operations crashed 1041.83% in 2023 before it skyrocketed 62.84% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 26458000.0 in 2021, then tumbled by 40.99% to 37303000.0 in 2022, then decreased by 26.21% to 47079000.0 in 2023, then plummeted by 40.02% to 65922000.0 in 2024, then surged by 62.84% to 24499000.0 in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Income from Continuing Operations are 24499000.0 (Q4 2025), 37270000.0 (Q3 2025), and 40139000.0 (Q2 2025).